Penumbra, Inc. (NYSE:PEN) Director Arani Bose Sells 12,000 Shares

Penumbra, Inc. (NYSE:PEN) Director Arani Bose sold 12,000 shares of Penumbra stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $283.77, for a total value of $3,405,240.00. Following the transaction, the director now owns 314,819 shares of the company’s stock, valued at $89,336,187.63. The trade was a 3.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Penumbra Trading Down 2.3 %

Shares of Penumbra stock opened at $268.89 on Friday. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The firm has a market cap of $10.36 billion, a price-to-earnings ratio of 790.84, a PEG ratio of 2.83 and a beta of 0.51. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The business has a 50-day moving average price of $274.49 and a 200-day moving average price of $242.13.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Equities research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Robert W. Baird increased their price objective on shares of Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Oppenheimer began coverage on shares of Penumbra in a report on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price objective on the stock. Bank of America started coverage on Penumbra in a research note on Friday, March 14th. They issued a “buy” rating and a $320.00 price objective on the stock. Truist Financial lifted their price target on shares of Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, StockNews.com cut shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $294.47.

Institutional Investors Weigh In On Penumbra

Several large investors have recently bought and sold shares of PEN. Wealth Enhancement Advisory Services LLC grew its stake in shares of Penumbra by 74.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,115 shares of the company’s stock worth $740,000 after buying an additional 1,332 shares in the last quarter. Employees Retirement System of Texas grew its position in Penumbra by 31.9% in the fourth quarter. Employees Retirement System of Texas now owns 5,273 shares of the company’s stock worth $1,252,000 after acquiring an additional 1,274 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in Penumbra in the fourth quarter worth about $760,000. Polar Asset Management Partners Inc. increased its stake in Penumbra by 10.5% during the fourth quarter. Polar Asset Management Partners Inc. now owns 122,126 shares of the company’s stock worth $29,002,000 after acquiring an additional 11,605 shares during the last quarter. Finally, Cache Advisors LLC purchased a new stake in Penumbra during the fourth quarter valued at approximately $534,000. Institutional investors own 88.88% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.